SciELO - Scientific Electronic Library Online

 
vol.34 issue3Transanal minimally invasive surgery (TAMIS) for local excision of selected rectal neoplasms: efficacy and outcomes in the first 11 patientsAssociation of sociodemographic and clinical factors with the self-image and self-esteem of individuals with intestinal stoma author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

Related links

Share


Journal of Coloproctology (Rio de Janeiro)

Print version ISSN 2237-9363On-line version ISSN 2317-6423

Abstract

SANTOS, Carlos Henrique Marques dos. Comparison between infliximab and adalimumab in the treatment of perianal fistulas in Crohn's disease. J. Coloproctol. (Rio J.) [online]. 2014, vol.34, n.3, pp.154-158. ISSN 2317-6423.  https://doi.org/10.1016/j.jcol.2014.05.001.

Introduction:

The fistulizing form of Crohn's disease (CD) represents a great challenge regarding treatment, especially perianal fistulas, for its high prevalence.

Objective:

To assess factors related to the response to surgical treatment associated with anti-TNF inpatients with CD and perianal fistulas.

Method:

Retrospective study of patients with CD and perianal fistulas who used IFX or ADA in association with surgical treatment.

Results:

30 patients with a mean age of 35 years were studied; 16 were treated with ADA (9 ADA + AZA) and 14 with IFX (10 IFX + AZA); ten of those treated with ADA responded, and of the six non-respondents, only one responded to IFX; eight responded to IFX, and among those non-respondents, no one showed response with ADA; among the respondents, there were 10 men and nine women; of those non-respondents, eight were men and 3 women; of those under 40 years, 16 responded compared with only three non-respondents; of those over 40 years, three responded versus eight non-respondents; as to the time elapsed between the onset of the disease and the beginning of anti-TNF, 14 (<2 years), one (2–5 years) and four (>5 years) responded, and five (<2 years), four (2–5 years) and two (>5 years) were non-respondents.

Conclusion:

There was no difference in response between the anti-TNF agents used; a better response was noted in those who used anti-TNF in combination with azathioprine, among women, in those under 40 years and in those treated within two years of the onset of the disease.

Keywords : Crohn's disease; Infliximab; Adalimumab; Perianal fistula; Age.

        · abstract in Portuguese     · text in English     · English ( pdf )